New UK genomics partnership set to accelerate development of diagnostic tools and improve outcomes for patients - MIDAS

New UK genomics partnership set to accelerate development of diagnostic tools and improve outcomes for patients

Cambridge based Congenica Ltd and the UK Northern Health Science Alliance announced today a strategic partnership to deliver more accurate diagnostic tools and improve outcomes for patients with genetic conditions.

The aim of the partnership is to accelerate the development of collaborations between Congenica Ltd, a clinical genome diagnostics and discovery company, and that of the leading universities and NHS hospital Trusts in the North of England. The first proof-of-principle agreement under the partnership has already been formed between Congenica Ltd and Central Manchester University Hospitals NHS Foundation Trust.

The overarching partnership will bring together clinical genetic expertise, molecular diagnostic testing and large-scale genome analytics to develop and implement the next generation sequencing based analysis pipelines, genome-wide interpretation and reporting tools for diagnostic testing. This unique system will be rolled out to a variety of different applications and available through service and licensing business models.

Congenica’s genome analytics platform, which is scalable and capable of processing many thousands of samples per year, is central to the partners’ ambitious plans. Congenica’s genome analytics platform uses state-of-the-art statistical and computational methods, and has the flexibility to evolve with the rapidly changing next generation sequencing technology and clinical applications.

Under the agreement between Congenica and Central Manchester University Hospitals NHS Foundation Trust, the partners will create a reference laboratory. Based at the Manchester Centre for Genomic Medicine, the reference laboratory will undertake genome screening of patients and their unaffected relatives in order to generate a comprehensive genetic profile and clinical report to support diagnosis, the clinical decision making, treatment choice, and counselling. The partnership will concentrate efforts on developmental disorders, which account for approximately 30% of all genetic disease, but will then follow-on with programs in other therapeutic indications such as ophthalmological, cardiovascular and neurological disease.

 

Leave a Reply

Contact Us

Contact us online or call
+44 (0) 161 237 4470